FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311554414> ?p ?o ?g. }

• W4311554414 endingPage "e2245081" @default.
• W4311554414 startingPage "e2245081" @default.
• W4311554414 abstract "Importance Quality assurance of molecular tumor boards (MTBs) is crucial in cancer genome medicine. Objective To evaluate the concordance of recommendations by MTBs and centrally developed consensus treatment recommendations at all 12 leading institutions for cancer genomic medicine in Japan using 50 simulated cases. Design, Setting, and Participants This was a prospective quality improvement study of 50 simulated cancer cases. Molecular tumor boards from 12 core hospitals independently recommended treatment for 50 cases blinded to the centrally developed consensus treatment recommendations. The study’s central committee consisted of representatives from all 12 core hospitals in Japan who selected the 50 simulated cases from The Cancer Genome Atlas database, including frequently observed genomic alterations. The central committee recommended centrally developed consensus treatment. The concordance rate for genomically matched treatments between MTBs and centrally developed consensus treatment recommendations was evaluated. Data analysis was conducted from January 22 to March 3, 2021. Exposures Simulated cases of cancer. Main Outcomes and Measures The primary outcome was concordance, defined as the proportion of recommendations by MTBs concordant with centrally developed consensus treatment recommendations. A mixed-effects logistic regression model, adjusted for institutes as a random intercept, was applied. High evidence levels were defined as established biomarkers for which the treatment was ready for routine use in clinical practice, and low evidence levels were defined as biomarkers for genomically matched treatment that were under investigation. Results The Clinical Practice Guidance for Next-Generation Sequencing in Cancer Diagnosis and Treatment (edition 2.1) was used for evidence-level definition. The mean concordance between MTBs and centrally developed consensus treatment recommendations was 62% (95% CI, 57%-65%). Each MTB concordance varied from 48% to 86%. The concordance rate was higher in the subset of patients with colorectal cancer (100%; 95% CI, 94.0%-100%), ROS1 fusion (100%; 95% CI, 85.5%-100%), and high evidence level A/R (A: 88%; 95% CI, 81.8%-93.0%; R:100%; 95% CI, 92.6%-100%). Conversely, the concordance rate was lower in cases of cervical cancer (11%; 95% CI, 3.1%-26.1%), TP53 mutation (16%; 95% CI, 12.5%-19.9%), and low evidence level C/D/E (C: 30%; 95% CI, 24.7%-35.9%; D: 25%; 95% CI, 5.5%-57.2%; and E: 18%; 95% CI, 13.8%-23.0%). Multivariate analysis showed that evidence level (high [A/R] vs low [C/D/E]: odds ratio, 4.4; 95% CI, 1.8-10.8) and TP53 alteration (yes vs no: odds ratio, 0.06; 95% CI, 0.03-0.10) were significantly associated with concordance. Conclusions and Relevance The findings of this study suggest that genomically matched treatment recommendations differ among MTBs, particularly in genomic alterations with low evidence levels wherein treatment is being investigated. Sharing information on matched therapy for low evidence levels may be needed to improve the quality of MTBs." @default.
• W4311554414 created "2022-12-27" @default.
• W4311554414 creator A5015679349 @default.
• W4311554414 creator A5017586108 @default.
• W4311554414 creator A5018459991 @default.
• W4311554414 creator A5020448557 @default.
• W4311554414 creator A5020847267 @default.
• W4311554414 creator A5027219752 @default.
• W4311554414 creator A5032761079 @default.
• W4311554414 creator A5033804823 @default.
• W4311554414 creator A5035237919 @default.
• W4311554414 creator A5037474733 @default.
• W4311554414 creator A5040676201 @default.
• W4311554414 creator A5041593880 @default.
• W4311554414 creator A5048207662 @default.
• W4311554414 creator A5055160098 @default.
• W4311554414 creator A5058800221 @default.
• W4311554414 creator A5061361157 @default.
• W4311554414 creator A5062748030 @default.
• W4311554414 creator A5062750272 @default.
• W4311554414 creator A5064272098 @default.
• W4311554414 creator A5064708494 @default.
• W4311554414 creator A5075812843 @default.
• W4311554414 creator A5080208801 @default.
• W4311554414 creator A5083124300 @default.
• W4311554414 creator A5083659938 @default.
• W4311554414 creator A5088984746 @default.
• W4311554414 date "2022-12-05" @default.
• W4311554414 modified "2023-10-01" @default.
• W4311554414 title "Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan" @default.
• W4311554414 cites W2065477010 @default.
• W4311554414 cites W2103724490 @default.
• W4311554414 cites W2161375781 @default.
• W4311554414 cites W2178034026 @default.
• W4311554414 cites W2276287001 @default.
• W4311554414 cites W2412140884 @default.
• W4311554414 cites W2464234320 @default.
• W4311554414 cites W2566723262 @default.
• W4311554414 cites W2787553551 @default.
• W4311554414 cites W2888034354 @default.
• W4311554414 cites W2896448590 @default.
• W4311554414 cites W2913665520 @default.
• W4311554414 cites W2938206352 @default.
• W4311554414 cites W3033196316 @default.
• W4311554414 cites W3089562193 @default.
• W4311554414 cites W3097377793 @default.
• W4311554414 cites W3107834112 @default.
• W4311554414 cites W3114569141 @default.
• W4311554414 cites W4251286630 @default.
• W4311554414 cites W4255095486 @default.
• W4311554414 doi "https://doi.org/10.1001/jamanetworkopen.2022.45081" @default.
• W4311554414 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36469316" @default.
• W4311554414 hasPublicationYear "2022" @default.
• W4311554414 type Work @default.
• W4311554414 citedByCount "4" @default.
• W4311554414 countsByYear W43115544142023 @default.
• W4311554414 crossrefType "journal-article" @default.
• W4311554414 hasAuthorship W4311554414A5015679349 @default.
• W4311554414 hasAuthorship W4311554414A5017586108 @default.
• W4311554414 hasAuthorship W4311554414A5018459991 @default.
• W4311554414 hasAuthorship W4311554414A5020448557 @default.
• W4311554414 hasAuthorship W4311554414A5020847267 @default.
• W4311554414 hasAuthorship W4311554414A5027219752 @default.
• W4311554414 hasAuthorship W4311554414A5032761079 @default.
• W4311554414 hasAuthorship W4311554414A5033804823 @default.
• W4311554414 hasAuthorship W4311554414A5035237919 @default.
• W4311554414 hasAuthorship W4311554414A5037474733 @default.
• W4311554414 hasAuthorship W4311554414A5040676201 @default.
• W4311554414 hasAuthorship W4311554414A5041593880 @default.
• W4311554414 hasAuthorship W4311554414A5048207662 @default.
• W4311554414 hasAuthorship W4311554414A5055160098 @default.
• W4311554414 hasAuthorship W4311554414A5058800221 @default.
• W4311554414 hasAuthorship W4311554414A5061361157 @default.
• W4311554414 hasAuthorship W4311554414A5062748030 @default.
• W4311554414 hasAuthorship W4311554414A5062750272 @default.
• W4311554414 hasAuthorship W4311554414A5064272098 @default.
• W4311554414 hasAuthorship W4311554414A5064708494 @default.
• W4311554414 hasAuthorship W4311554414A5075812843 @default.
• W4311554414 hasAuthorship W4311554414A5080208801 @default.
• W4311554414 hasAuthorship W4311554414A5083124300 @default.
• W4311554414 hasAuthorship W4311554414A5083659938 @default.
• W4311554414 hasAuthorship W4311554414A5088984746 @default.
• W4311554414 hasBestOaLocation W43115544141 @default.
• W4311554414 hasConcept C121608353 @default.
• W4311554414 hasConcept C126322002 @default.
• W4311554414 hasConcept C143998085 @default.
• W4311554414 hasConcept C151956035 @default.
• W4311554414 hasConcept C160798450 @default.
• W4311554414 hasConcept C19527891 @default.
• W4311554414 hasConcept C512399662 @default.
• W4311554414 hasConcept C71924100 @default.
• W4311554414 hasConceptScore W4311554414C121608353 @default.
• W4311554414 hasConceptScore W4311554414C126322002 @default.
• W4311554414 hasConceptScore W4311554414C143998085 @default.
• W4311554414 hasConceptScore W4311554414C151956035 @default.
• W4311554414 hasConceptScore W4311554414C160798450 @default.
• W4311554414 hasConceptScore W4311554414C19527891 @default.
• W4311554414 hasConceptScore W4311554414C512399662 @default.

• next